Long-term safety of barzolvolimab for chronic hives
Part of Immune system & allergy, Skin clinical trials.
This study is a long-term extension of the barzolvolimab trial for people with chronic spontaneous urticaria (CSU). It tests the continued safety and effectiveness of barzolvolimab over a longer period for those who have already completed the initial phase 3 study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the earlier phase 3 study of barzolvolimab (either CDX0159-12 or CDX0159-13).
- You need to have a recorded UAS7 score (daily hives and itch count) from weeks 64 to 68 of that earlier study.
- You should not have any other itchy skin condition besides chronic hives (CSU).
- If you could become pregnant or father a child, you must agree to use effective birth control during the study and for 150 days after the last dose.
- You must be willing to use a daily electronic diary to track your symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
This Phase 4 study looks at whether extending the time between omalizumab injections can still control chronic spontaneous hives (CSU). It may help some people need fewer injections while keeping symptoms under control.
This study follows people with chronic spontaneous urticaria (long-lasting hives with no clear cause) who are starting a new medicine called remibrutinib or dupilumab. It aims to see how well these treatments work in everyday life.
This trial tests a new medication (HRS-3095) for chronic spontaneous urticaria—persistent hives that don't go away despite taking standard antihistamine pills. If your hives have lasted months and remain poorly controlled, this study may help you find relief.
This study observes how well remibrutinib works for people with chronic hives (CSU) in everyday medical practice. It compares three groups based on treatments you have tried, and checks if switching to remibrutinib helps control symptoms.
This study follows people with chronic hives (CSU) who start taking remibrutinib as part of their normal care. It looks at how well the medicine works in real life over 24 months.
Hear when a new Chronic Spontaneous Urticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.